



### Emerging Taxane Therapy

Peter Bjerkerot, RN, OCN

Since the introduction of Taxane therapy in the US, breast cancer patients have had a new weapon in their fight with the disease. The earlier formulations of both Taxol and Taxotere used a solvent in order to make a solution that could be delivered as an IV form. One of the biggest issues that patients face with regard to side effects is not from the active molecules, but from the solvents used. With the advent of nanoparticle technology, a new form of paclitaxel has been created that utilizes stable molecules of albumin to encapsulate the paclitaxel resulting in an IV form that is solvent through.

The presentation focused on mechanism of action, overall efficacy, and side effects. Nursing interventions were presented in practical interventions that nurses and the entire Oncology Team can utilize to minimize or manage expected side effects.

### Advances in the Treatment for Patients with Multiple Myeloma

Joseph Tariman, RN, MN, ARNP-BC, OCN

This lecture covered an overview of multiple myeloma, a B cell malignancy of the plasma cells. Despite advances in high-dose chemotherapy and stem cell transplantation, relapses are inevitable. New therapeutic agents such as lenalidomide and bortezomib that have shown promising clinical use in patients with relapsed or refractory multiple myeloma were discussed. The therapeutic applications and nursing management of common side effects of these novel agents with a focus on bortezomib (Velcade), which is a proteasome inhibitor, were presented. OA

